

Listing of the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently amended) A method of reducing the viability of a tumor cell, comprising administering to the tumor cell ~~an attenuated strain of~~ vesicular stomatitis virus, wherein said tumor cell is a melanoma cell,
wherein the virus is contained in a cell infected with the virus and
wherein the administering comprises administering the virus-infected cell.
2. (Cancelled).
3. (Original) The method of claim 1, wherein the tumor cell is PKR-/-; STAT1-/-; or both PKR-/- and STAT1-/-.
- 4-6. (Cancelled).
7. (Currently amended) The method of claim ~~6~~1, wherein the virus is unable to inactivate PKR activity within the tumor cell.
8. (Cancelled).
9. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M1.
10. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M2.
11. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M3.
12. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M4.

13. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M5.

14. (Currently amended) The method of claim 1, wherein the tumor cell is in a mammalian subject and the virus is administered to the tumor cell by intravenous, ~~intranasal~~, intraperitoneal or intratumoral administration to the subject.

15. (Currently amended) The method of claim 14, wherein the mammalian subject is a human ~~or a non-human mammal~~.

16. (Cancelled)

17. (Currently amended) A method of reducing the viability of a tumor cell within a population of ~~tumor cells and non-tumor cells~~ comprising administering ~~an attenuated strain of~~ vesicular stomatitis virus to the population of cells,

wherein the population of cells comprises tumor cells and non-tumor cells,

wherein the tumor cells are melanoma cells ~~and,~~

wherein the virus is able to selectively infect and kill reduce the viability of the tumor cell, and

wherein the virus is contained in a cell infected with the virus and

wherein the administering comprises administering the virus-infected cell.

18. (Original) The method of claim 17, wherein the virus is unable to inactivate PKR activity in the tumor cell.

19. (Currently amended) The method of claim ~~18~~17, further comprising treating the population of cells with interferon prior to administering the virus.

20. (New) The method of claim 14, wherein the mammalian subject is a non-human mammal.